Rhumbline Advisers Lexicon Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 145,939 shares of LXRX stock, worth $143,020. This represents 0.0% of its overall portfolio holdings.
Number of Shares
145,939
Previous 152,785
4.48%
Holding current value
$143,020
Previous $256,000
10.55%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding LXRX
# of Institutions
141Shares Held
238MCall Options Held
459KPut Options Held
133K-
Artal Group S.A. Luxembourg, N4136MShares$133 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$38.1 Million3.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA11MShares$10.8 Million0.41% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$9.69 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.09MShares$7.93 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $185M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...